Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Shares Outstanding (Diluted Average) (2016 - 2023)

Apyx Medical (APYX) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $34.6 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Shares Outstanding (Diluted Average) changed 0.31% year-over-year to $34.6 million, compared with a TTM value of $34.6 million through Dec 2023, changed 0.31%, and an annual FY2023 reading of $34.6 million, changed 0.31% over the prior year.
  • Shares Outstanding (Diluted Average) was $34.6 million for Q4 2023 at Apyx Medical, roughly flat from $34.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $34.6 million in Q4 2023 and bottomed at $34.1 million in Q4 2019.
  • Average Shares Outstanding (Diluted Average) over 5 years is $34.4 million, with a median of $34.3 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Diluted Average) fell 0.86% in 2019, then grew 0.54% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $34.1 million in 2019, then rose by 0.42% to $34.2 million in 2020, then increased by 0.35% to $34.3 million in 2021, then grew by 0.54% to $34.5 million in 2022, then increased by 0.31% to $34.6 million in 2023.
  • Business Quant data shows Shares Outstanding (Diluted Average) for APYX at $34.6 million in Q4 2023, $34.5 million in Q4 2022, and $34.3 million in Q4 2021.